Some Republicans in Congress question federal health spending on climate change, arguing other health crises, like opioid overdose deaths and child nutrition, are more urgent.
The FDA is still lacking a Senate-confirmed leader, but the agency is at the center of several major policy battles. Lawmakers this year must renew the bill that authorizes drug companies to pay "user fees," which enable the agency to hire additional reviewers to speed the approval of drugs.